Mr. Herrera, Who Will Join The Company As Its Vice President Of Growth And Strategic Partnerships, Has 15+ Years Of Global Life Sciences Experience And Will Help To Drive MINDCURE’s Commercial Focus And Strategic Partnerships
Psychedelics
Breaking News: MINDCURE (CSE: MCUR | OTC: MCURF) Announces Partnership with Speak Ai to Enhance iSTRYM, the Company’s Psychedelic Digital Therapeutics Technology Platform
Utilizing Speak Ai’s technology, iSTRYM will provide-AI-driven intelligence to help therapists identify the most efficient and efficacious outcomes for patients of psychedelic assisted psychotherapy
Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug Applications
Cybin prepares two drug candidates, CYB003 and CYB004 for Investigational New Drug applications.
GH Research Announces Closing of $125 Million Oversubscribed Series B Financing
Ireland-based GH Research has just raised $125 million in an oversubscribed Series B financing round.
Mydecine Announces Launch of Cutting-Edge Therapeutic Compound Screening
Mydecine commences screening psilocybin-based drug candidates.
How Cannabis Became the Gateway Drug…For Psychedelic Drug Normalization
Forty years ago, cannabis was labelled "a Gateway Drug" to harder drug use -- such as psychedelics. Today, cannabis is the Gateway Drug to psychedelics legalization.
The Mental Health Crisis: A Pandemic Becomes A Catastrophe
Two pandemics are currently afflicting the planet. While our governments focus on the smaller one (COVID-19), the larger one (the Mental Health Crisis) is rapidly spiralling out of control.
Peter Thiel-Backed Psychedelics Firm Buys Majority of Brain-Control Interface Firm
ATAI Life Sciences, a biosciences company backed by venture capitalist and freedom-loving billionaire Peter Thiel that specializes in experimental treatment of mental disorders with psychedelic drugs, has bought out a majority stake in a company working to meld the mind with machines.
MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors
MINDCURE increases its strategic investment in ATMA Journey Centers and deploys its iSTRYM digital therapeutics platform.
atai Life Sciences acquires majority stake in Psyber, Inc., to develop Brain Computer Interface-enabled digital therapeutics targeting mental health disorders
atai acquires a majority stake in Delaware-based Psyber, Inc., which has a strong focus on digital therapeutics.
Mydecine Announces Four Lead Novel Drug Candidates and Prepares for Pre-IND Meetings with the FDA and Health Canada To Prepare For Human Clinical
Mydecine announces several steps in its drug R&D, including four new novel drug candidates.
Psychedelic Stocks Primed For atai-MindMed Bounce
Both the atai Life Sciences IPO and a MindMed uplisting to the NASDAQ are highly anticipated events. They could occur within weeks -- or even days -- of each other.
California Senators Approve Bill To Legalize Possession Of Psychedelics Like LSD, MDMA And Psilocybin
A bill to decriminalize psychedelics in California and create a working group to study broader reform advanced through a Senate committee on Tuesday.
Hard Numbers On The Huge Potential Of Psychedelic Drug Development
Drug development is expensive. It is also EXTREMELY lucrative. We take a close look at this revenue potential.
Third Massachusetts City Approves Psychedelics Decriminalization Measure
Another Massachusetts city has approved a measure to deprioritize enforcement of laws against the possession, use and distribution of a wide range of psychedelics such as psilocybin and ayahuasca.